Rentokil Initial Fell While Profit Rose

Rentokil Initial reported higher revenue and profit in its latest half year, with net margin moving from 4.9% to 5.5%. Holding Rentokil Initial from the start of the year would have meant a 21.9% loss, including dividends. If you had bought on 1 January, that gap between improving results and falling capital value would feel uncomfortable. The real question is what clues were already on record before that drop unfolded.

Rentokil Initial has already moved. See which of 8 high quality undervalued stocks still trade below our estimates.

The Two Rentokil Initial Stories Investors Were Weighing

The shares cost £4.47 at the start of the period. Rentokil Initial sat between two well-argued stories about what that price really implied.

The bullish narrative pointed to a Fair Value of £5.5, a price level those optimistic assumptions supported, built on digital tools, AI-driven retention and smarter pricing that, in this view, could drive margins well above 20% in North America.

The more cautious case put Fair Value at £4.24, a level tied to slower revenue growth and margin gains, with particular concern around delayed Terminix integration and rising termite warranty claim costs.

What The Results Put To The Test For Rentokil Initial

Rentokil Initial reported H1 2026 revenue of US$3.589b and net income of US$196m, with net margin at 5.5% versus 4.9% a year earlier. That shift supported the optimistic story that focused on improving profitability, although margin levels still left plenty of room before the bullish case on substantially higher earnings was proven.

The useful takeaway is clear. When a thesis rests on margin expansion, you track margin itself. For any other company, compare the original margin assumption with each new report before considering how the share price has moved.

What Rentokil Initial’s Lower Price Now Asks Of You

Rentokil Initial now trades at £3.39, with the year to date move down 21.9% from £4.47. The selected Narrative’s Fair Value sits above the current price, based on confidence in how data tools, AI and the North American footprint could influence future earnings power.

The key judgement is whether Rentokil Initial can keep turning its North America transformation and global efficiency program into durable margin gains and cash generation, while termite related cash outflows stay manageable enough not to choke reinvestment.

"The main thing that has to go right is that Rentokil Initial continues to turn its North America transformation and global efficiency program into sustained margin accretion and cash generation, while keeping termite-related cash outflows and claims volatility under control."

One Narrative disagrees with today's price. → See where this Narrative says Rentokil Initial should trade

How Could You Get There Earlier?

Passing on this one could have spared you a loss. Where might you find the opposite surprise? Start looking for companies whose prices leave room for a better outcome than investors expect. These three trade below our estimated value.

• Company 1 - 21% below our estimate - uses a dispersed legal-services platform where partners move for more aligned incentives.
• Company 2 - 18% below our estimate - scales in-house supplement production as casual gym users adopt daily powder routines.
• Company 3 - 28% below our estimate - runs a unified technology investment platform that processes larger inflows without parallel costs.

That is three of the list. See the full list of 9 financially solid companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com